Related references
Note: Only part of the references are listed.Natural Protein Tolerance and Metabolic Control in Patients with Hereditary Tyrosinaemia Type 1
Ozlem Yilmaz et al.
NUTRIENTS (2020)
Daily variation of NTBC and its relation to succinylacetone in tyrosinemia type 1 patients comparing a single dose to two doses a day
Nienke S. Kienstra et al.
JOURNAL OF INHERITED METABOLIC DISEASE (2018)
Diagnosis and treatment of tyrosinemia type I: a US and Canadian consensus group review and recommendations
Jeffrey M. Chinsky et al.
GENETICS IN MEDICINE (2017)
Presumptive brain influx of large neutral amino acids and the effect of phenylalanine supplementation in patients with Tyrosinemia type 1
Willem G. van Ginkel et al.
PLOS ONE (2017)
Long-term cognitive functioning in individuals with tyrosinemia type 1 treated with nitisinone and protein-restricted diet
Maria Ignacia Garcia et al.
MOLECULAR GENETICS AND METABOLISM REPORTS (2017)
Neurocognitive outcome in tyrosinemia type 1 patients compared to healthy controls
Willem G. van Ginkel et al.
ORPHANET JOURNAL OF RARE DISEASES (2016)
Impaired Cognitive Functioning in Patients with Tyrosinemia Type I Receiving Nitisinone
Fatiha Bendadi et al.
JOURNAL OF PEDIATRICS (2014)
Cross-sectional study of 168 patients with hepatorenal tyrosinaemia and implications for clinical practice
Sebene Mayorandan et al.
ORPHANET JOURNAL OF RARE DISEASES (2014)
Recommendations for the management of tyrosinaemia type 1
Corinne de Laet et al.
ORPHANET JOURNAL OF RARE DISEASES (2013)
Heterogeneity of follow-up procedures in French and Belgian patients with treated hereditary tyrosinemia type 1: results of a questionnaire and proposed guidelines
Manuel Schiff et al.
JOURNAL OF INHERITED METABOLIC DISEASE (2012)
Single dose NTBC-treatment of hereditary tyrosinemia type I
A. Schlune et al.
JOURNAL OF INHERITED METABOLIC DISEASE (2012)
Corneal opacities associated with NTBC treatment
S Ahmad et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2002)
Share Paper
